EMBECTA CORP. (EMBC) Spending and interest coverage
- R&D / revenue · 12 months: Value 1.98%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 2.48%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 1.98% | Research and development expense / revenue. Period ending 2026-06-30. $20.20M ÷ $1.02B × 100 ≈ 1.98% |
| Stock-based compensation / revenue · 12 months | 2.48% | Share-based compensation / revenue. Period ending 2026-06-30. $25.30M ÷ $1.02B × 100 ≈ 2.48% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 20.20M USD | Research and Development Expense |
| Revenue | 1.02B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 25.30M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 223.50M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $20.20M | $1.02B | $25.30M | $223.50M | (m) | 1.98% | 2.48% | (m) | (m) |
| 2026-03-31 | $19.00M | $1.04B | $27.00M | $268.80M | (m) | 1.82% | 2.59% | (m) | (m) |
| 2025-12-31 | $21.60M | $1.08B | $28.60M | $296.70M | (m) | 2.00% | 2.65% | (m) | (m) |
| 2025-09-30 | $37.30M | $1.08B | $31.60M | $242.10M | (m) | 3.45% | 2.92% | (m) | (m) |
| 2025-06-30 | $52.50M | $1.10B | $28.30M | $211.80M | (m) | 4.76% | 2.57% | (m) | (m) |
| 2025-03-31 | $68.50M | $1.08B | $28.70M | $173.70M | (m) | 6.35% | 2.66% | (m) | (m) |
| 2024-12-31 | $78.90M | $1.11B | $27.90M | $150.00M | (m) | 7.12% | 2.52% | (m) | (m) |
| 2024-09-30 | $78.80M | $1.12B | $26.30M | $166.80M | (m) | 7.02% | 2.34% | (m) | (m) |
| 2024-06-30 | $82.60M | $1.12B | $25.00M | $166.40M | (m) | 7.38% | 2.23% | (m) | (m) |
| 2024-03-31 | $84.80M | $1.13B | $24.20M | $161.80M | (m) | 7.49% | 2.14% | (m) | (m) |
| 2023-12-31 | $88.50M | $1.12B | $23.30M | $178.20M | (m) | 7.88% | 2.08% | (m) | (m) |
| 2023-09-30 | $85.20M | $1.12B | $21.50M | $221.50M | (m) | 7.60% | 1.92% | (m) | (m) |
| 2023-06-30 | $79.50M | $1.11B | $21.00M | $192.70M | (m) | 7.14% | 1.89% | (m) | (m) |
| 2023-03-31 | $71.20M | $1.12B | $21.50M | $238.50M | (m) | 6.37% | 1.92% | (m) | (m) |
| 2022-12-31 | $67.10M | $1.12B | $19.60M | $281.80M | (m) | 6.01% | 1.76% | (m) | (m) |
| 2022-09-30 | $66.90M | $1.13B | $18.70M | $309.60M | (m) | 5.92% | 1.66% | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $63.30M | $1.17B | $12.80M | $492.00M | (m) | 5.43% | 1.10% | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $61.40M | $1.09B | $12.70M | $486.50M | (m) | 5.66% | 1.17% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |